RxDoctor Payments Data

Stephanie Green, MD

Family Medicine · Long Beach, CANPI 1427062462

Payments from drug & device makers

$2,059in general payments, 2019–2025

Across 78 payments — averaging $26.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$367
  • Kyowa Kirin, Inc.$257
  • Endo Pharmaceuticals Inc.$187
  • Boehringer Ingelheim$184
  • AstraZeneca$154
  • GSK$116
  • plus $794 from 18 others

What the payments were for

  • Food & beverage$2,059100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,059 in reported general payments places this provider in the 80th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$54,358
Medicare patients
123
Services billed
731

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SynthroidLevothyroxine Sodium24$1,420
Levothyroxine Sodium57$829
Olmesartan Medoxomil12$601
Metoprolol Succinate17$535
Rosuvastatin Calcium36$510
Losartan Potassium33$496
Amlodipine Besylate60$434
Atorvastatin Calcium53$386
Sertraline Hcl29$375
Pantoprazole Sodium24$364
Montelukast Sodium16$235
Simvastatin19$216
Alendronate Sodium19$155
Fluoxetine Hcl18$147
Hydrochlorothiazide31$144

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieSynthroid$74$1,42024 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 10,533 family medicine providers in California.

Other family medicine in Long Beach

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →